{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:44:40Z","timestamp":1766587480773,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014569","name":"Sociedad Espa\u00f1ola de Farmacia Hospitalaria","doi-asserted-by":"publisher","award":["5200\u20ac"],"award-info":[{"award-number":["5200\u20ac"]}],"id":[{"id":"10.13039\/501100014569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The aim of this study was to determine the psychometric properties of the Spanish-language version of the HIV-Symptom Index (HIV-SI) questionnaire in Spanish patients undergoing antiretroviral therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between 2014 and 2016, an observational, multicenter, prospective cohort study was conducted in seventeen Spanish hospitals to validate HIV-SI questionnaire in terms of: construct validity (confirmatory factor analysis), internal consistency (Cronbach\u2019s alpha), convergent validity (Pearson\u2019s correlation coefficient) and Known-group validity. In addition, a sensitivity to change analysis was also performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 232 patients were included in the study. They had a mean age of 46.17 (SD9.82) and were 75% male. The median overall score for the HIV-SI was 10 (IQR 4\u2013 19.5) and the most common symptoms reported were feelings of nervousness or anxiety, fatigue or energy loss, feeling sad or depressed, stomach pain or bloating, and difficulty sleeping. In the current study, the Spanish HIV-SI questionnaire showed a high internal consistency (\u03b1\u2009=\u20090.89) and adequate construct validity (CFI and TLI\u2009&gt;\u20090.90). When contrasted with the MOS-HIV questionnaire, an inverse correlation was found. It showed a good association with the mental (<jats:italic>r<\/jats:italic>=-0.61; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) and physical score (<jats:italic>r<\/jats:italic>=-0.60; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). In a multivariate analysis, the age of the patient, female condition, hepatitis C coinfection, concomitant treatment and non-adherence resulted in a higher HIV-SI score.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study has shown that the Spanish HIV-SI is a valid and reliable self-administered PROM for routine measurement of patient- reported symptoms among Spanish patients on antiretroviral treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-024-00780-2","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T11:01:42Z","timestamp":1727780502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Psychometric characteristics of the Spanish version of the HIV Symptom Index"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0852-5496","authenticated-orcid":false,"given":"Olatz","family":"Ibarra-Barrueta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oihana","family":"Mora-Atorrasagasti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itziar","family":"Palacios-Zabalza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urko","family":"Aguirre-Larracoechea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Legarreta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerea","family":"Gonz\u00e1lez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"780_CR1","unstructured":"Documento de consenso de gesida\/plan nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualizaci\u00f3n enero 2022). https:\/\/gesida-seimc.org\/wp-content\/uploads\/2022\/05\/GuiaGeSIDAPlanNacionalSobreElSidaRespectoAlTratamientoAntirretroviralEnAdultosInfectadosPorElVirusDeLaInmunodeficienciaHumanaActualizacionEnero2022.pdf [Last accessed: July 28, 2023]"},{"key":"780_CR2","doi-asserted-by":"publisher","unstructured":"Morillo-Verdugo R, Polo R, Knobel H et al (2020) Consensus document on enhancing medication adherence in patients with the human immunodeficiency virus receiving antiretroviral therapy. Farm Hosp 44(4):163\u2013173; https:\/\/doi.org\/10.7399\/fh.11441","DOI":"10.7399\/fh.11441"},{"issue":"5","key":"780_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/00042560-200112150-00006","volume":"28","author":"A Ammassari","year":"2001","unstructured":"Ammassari A, Murri R, Pezzotti P et al (2001) Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 28(5):445\u2013449. https:\/\/doi.org\/10.1097\/00042560-200112150-00006","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"780_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1310\/R8M7-EQ0M-CNPW-39FC","volume":"2","author":"S Duran","year":"2001","unstructured":"Duran S, Spire B, Raffi F, Walter V et al (2001) Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2(1):38\u201345. https:\/\/doi.org\/10.1310\/R8M7-EQ0M-CNPW-39FC","journal-title":"HIV Clin Trials"},{"issue":"18","key":"780_CR5","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1097\/00002030-200112070-00012","volume":"15","author":"S Duran","year":"2001","unstructured":"Duran S, Sav\u00e8s M, Spire B et al (2001) Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodistrophy. AIDS 15(18):2441\u20132444. https:\/\/doi.org\/10.1097\/00002030-200112070-00012","journal-title":"AIDS"},{"issue":"4","key":"780_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1080\/09540120802301824","volume":"21","author":"V Cooper","year":"2009","unstructured":"Cooper V, Gellaitry G, Hankins M et al (2009) The influence of symptom experiences and attributions on adherence to highly active antiretroviral therapy (HAART): a six-month prospective, follow-up study. AIDS Care 21(4):520\u2013528. https:\/\/doi.org\/10.1080\/09540120802301824","journal-title":"AIDS Care"},{"key":"780_CR7","unstructured":"U.S. FDA (2009) Guidance for industry: Patient- Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Available from: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, Rockville MD| FDA [Last accessed: January 6, 2024]"},{"issue":"2","key":"780_CR8","first-page":"126","volume":"21","author":"AC Justice","year":"1999","unstructured":"Justice AC, Rabeneck L, Hays RD et al (1999) Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-report symptoms. Outcomes Committee of the AIDS clinical trials Group. J Acquir Immune Defic Syndr 21(2):126\u2013133 PMID: 10360804","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"780_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/pds.1907","volume":"19","author":"RR Modayil","year":"2010","unstructured":"Modayil RR, Harugeri A, Parthasarathi G et al (2010) Adverse drug reactions to antiretroviral therapy (ART): an experience of spontaneous reporting and intensive monitoring from ART centre in India. Pharmacoepidemiol Drug Saf 19(3):247\u2013255. https:\/\/doi.org\/10.1002\/pds.1907","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"780_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00228-007-0339-8","volume":"63","author":"JM van der Foster","year":"2007","unstructured":"van der Foster JM, de Jong-van L (2007) Patient-reporting of side effects may provide an important source of information in clinical practice. Eur J Clin Pharmacol 63(10):979\u2013980. https:\/\/doi.org\/10.1007\/s00228-007-0339-8","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"780_CR11","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jpainsymman.2009.05.013","volume":"38","author":"KA Lee","year":"2009","unstructured":"Lee KA, Gay C, Portillo CJ et al (2009) Symptom experience in HIV-infected adults: a function of demographic and clinical characteristics. J Pain Symptom Manage 38(6):882\u2013893. https:\/\/doi.org\/10.1016\/j.jpainsymman.2009.05.013","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"780_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1468-1293.2010.00851.x","volume":"12","author":"C Clucas","year":"2011","unstructured":"Clucas C, Harding R, Lampe F et al (2011) Doctor-patient concordance during HIV treatment switching decision-making. HIV Med 12(2):87\u201396. https:\/\/doi.org\/10.1111\/j.1468-1293.2010.00851.x","journal-title":"HIV Med"},{"issue":"6","key":"780_CR13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1258\/095646206777323409","volume":"17","author":"R Harding","year":"2006","unstructured":"Harding R, Molloy T, Easterbrook P et al (2006) Is antiretroviral therapy associated with symptom prevalence and burden? Int J STD AIDS 17(6):400\u2013405. https:\/\/doi.org\/10.1258\/095646206777323409","journal-title":"Int J STD AIDS"},{"issue":"2","key":"780_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/00002030-200201250-00017","volume":"16","author":"JC Walsh","year":"2002","unstructured":"Walsh JC, Mandalia S, Gazzard BG (2002) Responses to a 1-month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 16(2):269\u2013277. https:\/\/doi.org\/10.1097\/00002030-200201250-00017","journal-title":"AIDS"},{"issue":"5","key":"780_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/s1055-3290(06)60263-x","volume":"12","author":"WL Holzemer","year":"2001","unstructured":"Holzemer WL, Hudson A, Kirksey KM et al (2001) The revised sign and symptom check-list for HIV (SSCHIVrev). J Assoc Nurses AIDS Care 12(5):60\u201370. https:\/\/doi.org\/10.1016\/s1055-3290(06)60263-x","journal-title":"J Assoc Nurses AIDS Care"},{"issue":"3","key":"780_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jpainsymman.2007.10.011","volume":"36","author":"DJ Wantland","year":"2008","unstructured":"Wantland DJ, Holzemer WL, Moezzi S et al (2008) A randomized controlled trial testing the efficacy of an HIV\/AIDS symptom management manual. J Pain Symptom Manage 36(3):235\u2013246. https:\/\/doi.org\/10.1016\/j.jpainsymman.2007.10.011","journal-title":"J Pain Symptom Manage"},{"issue":"Supl1","key":"780_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s0895-4356(01)00449-8","volume":"54","author":"AC Justice","year":"2001","unstructured":"Justice AC, Holmes W, Gifford AL et al (2001) Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 54(Supl1):77\u201390. https:\/\/doi.org\/10.1016\/s0895-4356(01)00449-8","journal-title":"J Clin Epidemiol"},{"key":"780_CR18","unstructured":"HIV-Symptom Index (HIV-SI or SDM) ePROVIDE\u2122\u2013 Online Support for Clinical Outcome Assessments. https:\/\/eprovide.mapi-trust.org\/instruments\/hiv-symptom-index [Last accessed: July 28, 2023]"},{"issue":"9","key":"780_CR19","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1097\/00002030-200406180-00011","volume":"18","author":"E Vincent","year":"2004","unstructured":"Vincent E, Bouhnik AD, Carrieri MP et al (2004) Impact of HAART-related side effects on unsafe sexual behaviours in HIV-infected injecting drug users: 7-year follow up. AIDS 18(9):1321\u20131325. https:\/\/doi.org\/10.1097\/00002030-200406180-00011","journal-title":"AIDS"},{"issue":"4","key":"780_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/QAI.0b013e31818cde21","volume":"49","author":"DJ Skiest","year":"2008","unstructured":"Skiest DJ, Krambrink A, Su Z et al (2008) Improved measures of Qualify of life, lipid profile and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170. J Acquir Immune Defic Syndr 49(4):377\u2013383. https:\/\/doi.org\/10.1097\/QAI.0b013e31818cde21","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"780_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/QAI.0b013e3181a572cf","volume":"51","author":"E DeJesus","year":"2009","unstructured":"DeJesus E, Young B, Morales-Ramirez JO et al (2009) Simplification of antiretroviral therapy to a single-tablet regimen consisting of Efavirenz, Emtricitabine, and Tenofovir versus unmodified antiretroviral therapy in virologically suppressed HIV-1 infected patients. J Acquir Immune Defic Syndr 51(2):163\u2013174. https:\/\/doi.org\/10.1097\/QAI.0b013e3181a572cf","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"780_CR22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/j.1524-4733.2007.00315.x","volume":"11","author":"RS Braithwaite","year":"2008","unstructured":"Braithwaite RS, Goulet J, Kudel I et al (2008) Quantifying the decrement in utility from perceived side effects of combination antiretroviral therapies in patients with HIV. Value Health 11(5):975\u2013979. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00315.x","journal-title":"Value Health"},{"issue":"4","key":"780_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1310\/hct1004-215","volume":"10","author":"B Spire","year":"2009","unstructured":"Spire B, Arnould B, Barbier F et al (2009) Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: the HIV-SQUAD (Symptom Quality of life adherence) Questionnaire\u00ae. HIV Clin Trials 10(4):215\u2013232. https:\/\/doi.org\/10.1310\/hct1004-215","journal-title":"HIV Clin Trials"},{"issue":"3","key":"780_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.7399\/fh.11127","volume":"43","author":"O Ibarra-Barrueta","year":"2019","unstructured":"Ibarra-Barrueta O, Mora-Atorrasagasti O, Aguirre U et al (2019) Pilot study to develop and validate a questionnaire based on HIV symptoms index. FarmHosp 43(3):87\u201393. https:\/\/doi.org\/10.7399\/fh.11127","journal-title":"FarmHosp"},{"issue":"Suppl 2","key":"780_CR25","first-page":"103","volume":"17","author":"X Bad\u00eda","year":"1999","unstructured":"Bad\u00eda X, Podzamczer D, L\u00f3pez-Lavid C et al (1999) Medicina basada en la evidencia y la validaci\u00f3n de cuestionarios de calidad de vida: la versi\u00f3n espa\u00f1ola del cuestionario MOS-HIV para la evaluaci\u00f3n de la calidad de vida en pacientes infectados por El VIH. GrupoEspa\u00f1ol De Validaci\u00f3n De Los cuestionarios MOS-HIV y MQOL-HIV [Evidence-based medicine and the validation of quality-of-life questionnaires: the Spanish version of the MOS-HIV questionnaire for the evaluation of the quality of life in patients infected by HIV]. EnfermInfeccMicrobiolClin 17(Suppl 2):103\u2013113 Spanish. PMID: 10605195","journal-title":"EnfermInfeccMicrobiolClin"},{"issue":"13","key":"780_CR26","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1097\/00002030-199909100-00017","volume":"13","author":"X Badia","year":"1999","unstructured":"Badia X, Podzamczer D, Garcia M et al (1999) A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients. Spanish MOS-HIV and MQOL-HIV Validation Group. Medical outcomes Study HIV Health Survey. AIDS 13(13):1727\u20131735. https:\/\/doi.org\/10.1097\/00002030-199909100-00017","journal-title":"AIDS"},{"issue":"4","key":"780_CR27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/00002030-200203080-00012","volume":"16","author":"H Knobel","year":"2002","unstructured":"Knobel H, Alonso J, Casado JL et al (2002) Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS 16(4):605\u2013613. https:\/\/doi.org\/10.1097\/00002030-200203080-00012","journal-title":"AIDS"},{"issue":"5","key":"780_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/QAI.0b013e3181fba6ab","volume":"55","author":"IM de Boer","year":"2010","unstructured":"de Boer IM, Prins JM, Sprangers MAG et al (2010) Using different calculations of pharmacy refill adherence to predict virological failure among HIV-infected patients. J Acquir Immune DeficSyndr 55(5):635\u2013640. https:\/\/doi.org\/10.1097\/QAI.0b013e3181fba6ab","journal-title":"J Acquir Immune DeficSyndr"},{"issue":"2","key":"780_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jval.2018.08.006","volume":"22","author":"PP Pednekar","year":"2019","unstructured":"Pednekar PP, \u00c1gh T, Malmen\u00e4s M et al (2019) Methods for measuring multiple medication adherence: a systematic review-report of the ISPOR Medication Adherence and Persistence Special Interest Group. Value Health 22(2):139\u2013156 Epub 2018 Oct 25. PMID: 30711058","journal-title":"Value Health"},{"issue":"2","key":"780_CR30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1037\/1082-989X.1.2.130","volume":"1","author":"RC MacCallum","year":"1996","unstructured":"MacCallum RC, Browne MW, Sugawara HM (1996) Power analysis and determination of sample size for covariance structure modeling. Psychol Methods 1(2):130\u2013149. https:\/\/doi.org\/10.1037\/1082-989X.1.2.130","journal-title":"Psychol Methods"},{"key":"780_CR31","unstructured":"Kelloway EK (1998) Using LISREL for Structural Equation Modeling: A Researchers Guide. Sage Publications, Inc. Chicago, IL: Scientific Software International, ISBN: 0761906266, 9780761906261"},{"key":"780_CR32","doi-asserted-by":"publisher","unstructured":"Middel B, van Sonderen E (2002) Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research. Int J Integr care e15. 2https:\/\/doi.org\/10.5334\/ijic.65","DOI":"10.5334\/ijic.65"},{"key":"780_CR33","doi-asserted-by":"publisher","unstructured":"Vittinghoff E, Glidden DV, Shiboski SC et al (2005) Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models (1st ed. 2005.). Springer New York. https:\/\/doi.org\/10.1007\/b138825https:\/\/psycnet.apa.org\/record\/2005-03155-000","DOI":"10.1007\/b138825"},{"issue":"12","key":"780_CR34","doi-asserted-by":"publisher","first-page":"e39015","DOI":"10.2196\/39015","volume":"8","author":"Z Wang","year":"2022","unstructured":"Wang Z, Zhu Y, Duan X et al (2022) HIV-Specific reported Outcome measures: systematic review of Psychometric Properties. JMIR Public Health Surveill 8(12):e39015. https:\/\/doi.org\/10.2196\/39015","journal-title":"JMIR Public Health Surveill"},{"issue":"4","key":"780_CR35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11136-010-9606-8","volume":"19","author":"LB Mokkink","year":"2010","unstructured":"Mokkink LB, Terwee CB, Patrick DL et al (2010) The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res 19(4):539\u2013549. https:\/\/doi.org\/10.1007\/s11136-010-9606-8","journal-title":"Qual Life Res"},{"issue":"6","key":"780_CR36","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1177\/1740774509352515","volume":"6","author":"A Regnault","year":"2009","unstructured":"Regnault A, Marfatia S, Louie M et al (2009) Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients. Clin Trials Dec 6(6):574\u2013584. https:\/\/doi.org\/10.1177\/1740774509352515","journal-title":"Clin Trials Dec"},{"issue":"8","key":"780_CR37","doi-asserted-by":"publisher","first-page":"e23726","DOI":"10.1371\/journal.pone.0023726","volume":"6","author":"P Cahn","year":"2011","unstructured":"Cahn P, Montaner J, Junod P et al (2011) Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV\/r maintenance therapy in HIV patients on the 1st PI-Based regimen. PLoS ONE 6(8):e23726. https:\/\/doi.org\/10.1371\/journal.pone.0023726","journal-title":"PLoS ONE"},{"issue":"5","key":"780_CR38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40271-015-0137-9","volume":"8","author":"J Gathe","year":"2015","unstructured":"Gathe J, Arribas JR, Van Lunzen J et al (2015) Patient-reported symptoms over 48 weeks in a randomized, Open-Label, phase 3b non-inferiority trial of adults with HIV switching to CoformulatedElvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-boosted protease inhibitor with Emtricitabine and Tenofovir DF. Patient 8(5):445\u2013454. https:\/\/doi.org\/10.1007\/s40271-015-0137-9","journal-title":"Patient"},{"issue":"6","key":"780_CR39","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1089\/apc.2012.0044","volume":"26","author":"EJ Edelman","year":"2012","unstructured":"Edelman EJ, Gordon K, Rodriguez-Barradas MC et al (2012) Vacs Project Team. Patient-reported symptoms on the antiretroviral regimen efavirenz\/emtricitabine\/tenofovir. AIDS Patient Care STDS 26(6):312\u2013319. https:\/\/doi.org\/10.1089\/apc.2012.0044","journal-title":"AIDS Patient Care STDS"},{"issue":"11","key":"780_CR40","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1080\/09540121.2012.656567","volume":"24","author":"LG Marc","year":"2012","unstructured":"Marc LG, Wang MM, Testa MA (2012) Psychometric evaluation of the HIV symptom distress scale. AIDS Care 24(11):1432\u20131441. https:\/\/doi.org\/10.1080\/09540121.2012.656567","journal-title":"AIDS Care"},{"issue":"6","key":"780_CR41","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jpainsymman.2022.02.337","volume":"63","author":"NL Wilson","year":"2022","unstructured":"Wilson NL, Hoffman TJ, Heath SL et al (2022) HIV Symptom clusters are similar using the dimensions of Symptom occurrence and distress. J Pain Symptom Manage 63(6):943\u2013952. https:\/\/doi.org\/10.1016\/j.jpainsymman.2022.02.337","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"780_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jpainsymman.2019.03.018","volume":"58","author":"Z Zhu","year":"2019","unstructured":"Zhu Z, Zhao R, Yan Hu (2019) Symptom clusters in people living with HIV: a systematic review. J Pain Symptom Manage 58(1):115\u2013133. https:\/\/doi.org\/10.1016\/j.jpainsymman.2019.03.018","journal-title":"J Pain Symptom Manage"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00780-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00780-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00780-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T23:05:29Z","timestamp":1727823929000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00780-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["780"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00780-2","relation":{},"ISSN":["2509-8020"],"issn-type":[{"type":"electronic","value":"2509-8020"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of the Basque Country in June 9th, 2011 and by the local committee at each hospital. The Spanish Agency for Medicines and Health Products (AEMPS), considered as a post-authorization study of observational prospective follow-up in October 24th, 2012. Patients\u2019 written consent to participate was obtained for the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the preparation of this manuscript the authors do not use any AI- technology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}},{"value":"The authors declare that they have no competing interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}